US biopharma Vertex Pharmaceuticals (Nasdaq: VRTX) has reported its fourth-quarter and full-year financial results.
Revenue for the quarter came in at $2.3 billion, exactly on the analyst consensus estimate and 11% up on the same period of 2021. For the full year, the figure was $8.93 billion, 18% more than the previous year.
Quarterly earnings per share were $3.15, up 5%, while for the full year, they rose 42% to $12.82.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze